CClinicalTrials.gg
Sign In
CompletedNCT04237818Updated Nov 30, 2020

The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect

An interventional study of Placebo drink and Chenopodium Formosanum and Fagopyrum Esculentum Extract drink in Skin Condition, sponsored by TCI Co., Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-30.

Sponsored by TCI Co., Ltd. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

To assess Chenopodium Formosanum and Fagopyrum Esculentum Extract on skin anti-aging

02

Conditions studied

  • Skin Condition

Browse trials for

03

In context

Skin Diseases

538 studies on the registry are indexed under Skin Diseases; 92 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 372 interventional studies indexed under Skin Diseases.

Browse Skin Diseases studies →

Lead sponsor

TCI Co., Ltd. is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adults aged between 20-65 years old
  • Subjects must read and sign the informed consent form after the study has been fully explained.
  • Subjects are willing to cooperate and comply with all of the regulation during the trial.
  • Subject should inform to investigator immediately if adverse effect is happened.
  • Subjects are willing to avoid UV overexposure during the trial (include indoor tanning treatment).

Exclusion criteria

Exclusion Criteria:

  • Subjects who have known cosmetic, drug or food allergies.
  • Subjects who have severe desquamation, tattoo, sunburn, peeling skin or other skin condition might impact measurement.
  • Subjects with any physical condition judged by the researcher not to be eligible for this study.
  • Subjects with uncontrollable physical condition such as high blood pressure, thyroid disease, diabetes, etc.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Those who are currently participating in other clinical trials or who have just concluded a clinical trial two weeks ago.
  • Women who have started contraceptive or change current hormone contraceptive methods within 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Placebo comparator
    Placebo drink

    Dietary Supplement: Placebo drink

  • Experimental
    Chenopodium Formosanum and Fagopyrum Esculentum Extract drink

    Dietary Supplement: Chenopodium Formosanum and Fagopyrum Esculentum Extract drink

Interventions

  • Dietary supplementPlacebo drink

    consume 2 bottle (30 mL) per day for 56 days

  • Dietary supplementChenopodium Formosanum and Fagopyrum Esculentum Extract drink

    consume 2 bottle (30 mL) per day for 56 days

06

What researchers measure

Primary outcomes

  1. The change of skin moisture

    Corneometer® CM825 is utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

    Time frame: Change from Baseline skin moisture at 8 weeks

  2. The change of skin elasticity

    Cutometer® dual MPA 580 is utilized to measure skin elasticity (parameter R2). Units: μm penetration depth into the probe opening, expressed as curves

    Time frame: Change from Baseline skin elasticity at 8 weeks

  3. The change of skin wrinkles

    3D Full-Face Skin Analyzer IRV is utilized to measure wrinkles. Units: arbitrary units

    Time frame: Change from Baseline skin wrinkles at 8 weeks

  4. The change of skin collagen density

    DermaLab® combo - 20 MHz High Freq. Ultrasound probe is utilized to scan and analyze skin collagen density. Units: Intensity score

    Time frame: Change from Baseline skin collagen density at 8 weeks

  5. The change of skin tone

    3D Full-Face Skin Analyzer IRV was utilized to measure skin tone. Units: arbitrary units

    Time frame: Change from Baseline skin tone at 8 weeks

  6. The change of skin brightness

    3D Full-Face Skin Analyzer IRV is utilized to measure skin brightness. Units: arbitrary units

    Time frame: Change from Baseline skin brightness at 8 weeks

  7. The change of skin melanin index

    Mexameter® MX 18 is utilized to measure skin melanin index. Units: arbitrary Mexameter® units (0-999)

    Time frame: Change from Baseline skin melanin index at 8 weeks

  8. The change of skin L*a*b* value

    Color Spectrophotometer SCM-104/108 is utilized to measure skin L\*a\*b\* value. Units: arbitrary units

    Time frame: Change from Baseline skin L*a*b* value at 8 weeks

Secondary outcomes

  1. The change of transepidermal water loss (TEWL)

    Tewameter® TM 300 is utilized to measure transepidermal water loss. Units: g/hm²

    Time frame: Change from Baseline TEWL at 8 weeks

  2. The change of skin texture

    3D Full-Face Skin Analyzer IRV is utilized to measure skin texture. Units: arbitrary units

    Time frame: Change from Baseline skin texture at 8 weeks

  3. The change of skin pores

    3D Full-Face Skin Analyzer IRV is utilized to measure skin pores. Units: arbitrary units

    Time frame: Change from Baseline skin pores at 8 weeks

  4. The change of skin spots

    3D Full-Face Skin Analyzer IRV is utilized to measure skin spots. Units: arbitrary units

    Time frame: Change from Baseline skin spots at 8 weeks

  5. The change of skin erythema level

    Mexameter® MX 18 is utilized to measure skin erythema level. Units: arbitrary Mexameter® units (0-999)

    Time frame: Change from Baseline skin erythema level at 8 weeks

  6. Self-assessment questionnaire

    Questionnaire is utilized to assess skin condition of the subjects. Units: score

    Time frame: 8 weeks

07

Study locations

1 site
  • China Medical University
    Taichung, 404, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04237818
Lead sponsor
TCI Co., Ltd.
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Feb 1, 2020
Primary completion
Apr 30, 2020
Completion
Aug 15, 2020
Last update
Nov 30, 2020

Study contacts

Hsiu-Mei Chiang, Prof.
principal investigator · China Medical University, China
Po-Yuan Wu, Dr.
study director · China Medical University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Skin Diseases→

Other studies from this sponsor

TCI Co., Ltd.

Start the discussion